Rajaie Soheila, Rezapour Aziz, Tajdini Masih, Salehbeygi Shahrzad, Azari Samad
Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
J Tehran Heart Cent. 2024 Apr;19(2):109-115. doi: 10.18502/jthc.v19i2.16200.
The concurrence of acute myocardial infarction (AMI) with COVID-19 can complicate the clinical conditions of patients and affect the patterns of hospital resource utilization. This study aimed to investigate and analyze the direct treatment costs of AMI patients with concurrent COVID-19.
This cross-sectional study collected and analyzed clinical data, including symptoms, readmission, and interventions, and treatment cost data for all patients at Tehran Heart Center using SPSS26 software. The mean medical costs of patients from January through May 2022 were also calculated.
The COVID-19 group was composed of 72.9% male and 27.1% female patients, whereas the non-COVID-19 group consisted of 67.3% male and 32.7% female patients. Most of the patients in the COVID-19 group (60%) were in the elderly age group (>65 y). The length of stay was 8.70±5.84 days for the COVID-19 group and 6.31±4.42 days for the non-COVID-19 group. The mortality rate in the COVID-19 group was 24%, higher than the 5% rate in the other group. Additionally, the average total treatment costs were $6384.54±$6760.13 in the COVID-19 group and $6362.49±$4343.07 in the non-COVID-19 group (P>0.78 and P>0.050).
The study found that the COVID-19 group had a significantly higher in-hospital mortality rate than the non-COVID-19 group. During the follow-up period, the incidence of complications (chest pain and heart failure) was higher in the non-COVID-19 group. It also showed that longer hospital stays resulted in higher treatment costs.
急性心肌梗死（AMI）与新型冠状病毒肺炎（COVID-19）并存会使患者临床情况复杂化，并影响医院资源利用模式。本研究旨在调查和分析合并COVID-19的AMI患者的直接治疗费用。
本横断面研究使用SPSS26软件收集并分析了德黑兰心脏中心所有患者的临床数据，包括症状、再次入院情况和干预措施，以及治疗费用数据。还计算了2022年1月至5月患者的平均医疗费用。
COVID-19组男性患者占72.9%，女性患者占27.1%；而非COVID-19组男性患者占67.3%，女性患者占32.7%。COVID-19组大多数患者（60%）为老年组（>65岁）。COVID-19组的住院时间为8.70±5.84天，非COVID-19组为6.31±4.42天。COVID-19组的死亡率为24%，高于另一组的5%。此外，COVID-19组的平均总治疗费用为6384.54±6760.13美元，非COVID-19组为6362.49±4343.07美元（P>0.78且P>0.050）。
研究发现，COVID-19组的院内死亡率显著高于非COVID-19组。在随访期间，非COVID-19组并发症（胸痛和心力衰竭）的发生率较高。研究还表明，住院时间延长导致治疗费用增加。
